



OPEN ACCESS

EDITED AND REVIEWED BY
Umang Swami,
The University of Utah, United States

*CORRESPONDENCE
Viktor Grünwald
✉ Viktor.Gruenwald@uk-essen.de

RECEIVED 22 November 2023
ACCEPTED 27 November 2023
PUBLISHED 01 March 2024

CITATION

Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong S-H, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J and Choueiri TK (2024) Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. *Front. Oncol.* 13:1343027. doi: 10.3389/fonc.2023.1343027

COPYRIGHT

© 2024 Grünwald, Powles, Eto, Kopyltsov, Rha, Porta, Motzer, Hutson, Méndez-Vidal, Hong, Winquist, Goh, Maroto, Buchler, Takagi, Burgents, Perini, He, Okpara, McKenzie and Choueiri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

Viktor Grünwald^{1*}, Thomas Powles², Masatoshi Eto³, Evgeny Kopyltsov⁴, Sun Young Rha⁵, Camillo Porta⁶, Robert Motzer⁷, Thomas E. Hutson⁸, María José Méndez-Vidal⁹, Sung-Hoo Hong¹⁰, Eric Winquist¹¹, Jeffrey C. Goh¹², Pablo Maroto¹³, Tomas Buchler¹⁴, Toshio Takagi¹⁵, Joseph E. Burgents¹⁶, Rodolfo Perini¹⁷, Cixin He¹⁸, Chinyere E. Okpara¹⁹, Jodi McKenzie²⁰ and Toni K. Choueiri²¹

¹Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany, ²Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, United Kingdom, ³Department of Urology, Kyushu University, Fukuoka, Japan, ⁴State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia, ⁵Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea, ⁶Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', Bari, Italy, ⁷Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ⁸Medical Oncology, Texas Oncology, Dallas, TX, United States, ⁹Department of Oncology, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain, ¹⁰Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea, ¹¹Department of Oncology, University of Western Ontario, London, ON, Canada, ¹²ICON Research, South Brisbane & University of Queensland, St Lucia, QLD, Australia, ¹³Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁴Department of Oncology, Charles University and Thomayer University Hospital, Prague, Czechia, ¹⁵Department of Urology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁶Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States, ¹⁷Clinical Research, Merck & Co., Inc., Rahway, NJ, United States, ¹⁸Biostatistics, Eisai Inc., Nutley, NJ, United States, ¹⁹Clinical Research, Eisai Ltd., Hatfield, United Kingdom, ²⁰Clinical Research, Eisai Inc., Nutley, NJ, United States, ²¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States

KEYWORDS

renal cell carcinoma, lenvatinib, pembrolizumab, sunitinib, bone metastases, liver metastases, lung metastases, sarcomatoid histology

A Corrigendum on

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

by Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong S-H, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J and Choueiri TK (2023) *Front. Oncol.* 13:1223282. doi: 10.3389/fonc.2023.1223282

In the published article, there was an error in the legend for Figure 3 and Supplementary Table 1 as published. Clarification that objective response rates and complete response rates were calculated based on the number of patients in each listed subgroup was omitted. The corrected legend of both appears below.

^aAs assessed by IRC per RECIST v1.1. ^bPercents were calculated based on listed subgroups.”

In the published article, there was an error in Figure 3 and Supplementary Table 1 as published. For both, percentages in the “complete response” column were incorrectly calculated as the number of patients with a complete response in each subgroup divided by all patients in the respective treatment arm (n=355 for lenvatinib + pembrolizumab; n=357 for sunitinib) instead of being divided by the number of patients in each applicable subgroup.

The corrected Figure 3 and its captions (also corrected per the above to “^aAs assessed by IRC per RECIST v1.1. ^bPercents were calculated based on listed subgroups.”) appear below.

The text did not account for the revisions made to the complete response rate mentioned above.

A correction has been made to Section 3.2.3 (*Objective response*), paragraph 2. This sentence previously stated:

“As expected, the rates of CRs were higher in patients without baseline bone metastases or baseline liver metastases, in patients who had baseline lung metastases, and in patients who had a prior

nephrectomy. While the number of patients with sarcomatoid features was small, the rates of CRs in patients without sarcomatoid features was higher than those of patients with sarcomatoid features.”

The corrected sentence appears below:

“As expected, the rates of CRs were higher in patients without baseline bone metastases, and in patients who had a prior nephrectomy. CR rates were similar irrespective of whether or not patients had baseline liver metastases.”

The Supplementary Table 1 has been updated directly in the original article.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 3

ORR^a and Odds Ratios for Lenvatinib + Pembrolizumab Versus Sunitinib Treatment in Subgroups of Interest. ^aAs assessed by IRC per RECIST v1.1. ^bPercents were calculated based on listed subgroups. CI, confidence interval; CR, complete response; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; IRC, independent review committee; ITT, intention to treat; L+P, lenvatinib + pembrolizumab; MSKCC, Memorial Sloan Kettering Cancer Center; ORR, objective response rate; RECIST v1.1, Response Evaluation Criteria In Solid Tumors version 1.1; S, sunitinib.